Reasons for treating secondary AML as de novo AML

European Journal of Haematology

Volumn 85, Issue 3, 2010, Pages 217-226

  Østgrd, Lene Sofie Granfeldt ^a   Kjeldsen, Eigil ^a   Holm, Mette Skov ^b   Brown, Peter De Nully ^c   Pedersen, Bjarne Bach ^d   Bendix, Knud ^a   Johansen, Preben ^b   Kristensen, Jørgen Schøler ^a   Nørgaard, Jan Maxwell ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; HYDROXYUREA; IDARUBICIN; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DENMARK; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REMISSION; TREATMENT DURATION; UNIVARIATE ANALYSIS; COHORT ANALYSIS; COMPLICATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REGISTER; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REGISTRIES; YOUNG ADULT;

EID: 77955820647     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01464.x     Document Type: Article

References (33)

1. Kalaycio M, Advani A, Pohlman B, Sekeres M, Tripp B, Rybicki L, Sobecks R. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. Am J Hematol 2008 83 : 831 4.
2. Grigg AP, Gibson J, Bardy PG, et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant 2007 13 : 560 7.
3. Braess J, Spiekermann K, Staib P, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009 113 : 3903 10.
4. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood 2006 107 : 3481 5.
5. Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, Champlin RE. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989 7 : 1637 45.
6. Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol 2007 20 : 29 37.
7. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009 113 : 4179 87.
8. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009 113 : 3666 72.
9. Rowe JM. Closer to the truth in AML. Blood 2009 113 : 4129 30.
10. Rizzieri DA, O'Brien JA, Broadwater G, et al. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 2009 115 : 2922 9.
11. Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009 145 : 318 32.
12. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, Moorman AV, Burnett AK. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009 145 : 598 605.
13. Norgaard JM, Olesen LH, Olesen G, Meyer K, Kristensen JS, Bendix K, Pedersen B, Kjeldsen E, Hokland P. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. Eur J Haematol 2001 67 : 221 9.
14. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: useful agent in the treatment of acute leukemia in adults. Blood 1968 32 : 507 23.
15. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003 21 : 4642 9.
16. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVONSAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007 109 : 3658 66.
17. Mitelman F. ISCN 1995:an international system for human cytogenetic nomenclature (1995):recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, USA, October 9-13, 1994.
18. Shafer LG, Tommerup N. ISCN 2005: an international system for human cytogenetic nomenclature (2005): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature.
19. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998 92 : 2322 33.
20. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001 98 : 1312 20.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976 33 : 451 8.
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985 103 : 620 5.
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991 78 : 325 9.
24. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006 108 : 1092 9.
25. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999 107 : 69 79.
26. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004 18 : 120 5.
27. Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C. Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of Karyotype. JCO 2004 22 : 2510 1. Correspondence.
28. Pedersen-Bjergaard J, Specht L, Larsen SO, Ersboll J, Struck J, Hansen HH, Hansen MM, Nissen NI. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987 2 : 83 8.
29. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 2009 115 : 3217 21.
30. Burnett A. K., Hills R. K., Wheatley K., Goldstone A. H., Prentice A. G., Milligan D. A sensitive risk score for directing treatment in younger patients with AML. Blood 108 10a. 2006. Abstract.
31. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 51 : 189 99.
32. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn.
33. Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Ostergaard M, Grimwade D, Hokland P. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010 115 : 198 205.